SCHEDULE 13G: Vanguard Group Discloses 6.32% Passive Stake in Keros Therapeutics Inc

The Vanguard Group has disclosed a 6.32% beneficial ownership stake in Keros Therapeutics Inc, holding 2,566,321 shares of common stock as of March 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 2,566,321 shares of Keros Therapeutics Inc common stock.
• This ownership represents 6.32% of the company's outstanding common stock.
• The filing date for this Schedule 13G was April 30, 2025, with the event date requiring the filing being March 31, 2025.
• Vanguard holds sole dispositive power over 2,518,131 shares and shared dispositive power over 48,190 shares.
• Vanguard holds shared voting power over 31,112 shares and no sole voting power.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Keros Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the company, as it represents a routine passive investment by a large institutional fund.

Positives

• A major institutional investor, The Vanguard Group, holds a significant stake, indicating inclusion in their investment portfolios, which can be viewed positively by the market.

Future Outlook

NA

Industry Context

This filing is a routine disclosure for large institutional investors like The Vanguard Group, indicating their passive ownership stake in Keros Therapeutics Inc. It reflects standard portfolio management activities, often related to index fund holdings, rather than a strategic investment decision aimed at influencing company operations.

Comparison to Industry Standards

• The 6.32% stake held by The Vanguard Group is a common level of passive institutional ownership for a large asset manager, consistent with their role in managing broad market index funds and ETFs. This type of filing is standard practice when an institutional investor's beneficial ownership crosses the 5% threshold.

Stakeholder Impact

• Shareholders: Provides transparency on significant institutional ownership, potentially signaling stability or inclusion in major funds, which can be reassuring.

Key Dates

Keywords

Keros Therapeutics, Vanguard Group, Schedule 13G, Common Stock, Institutional Ownership, SEC Filing, Investment Adviser, Beneficial Ownership